Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosis

Table 4 General information of patients and statistical summary of continuous numerical observation indexes

Indexes	Before treatment VS 6 months (n = 20)			Before treatment VS 12 months (n = 17)
Indexes	Before treatment	6 months	P value	Before treatment	12 months	P value
Oxygen partial pressure(mmHg)	69.05 ± 1.14	88.16 ± 15	< 0.001	67.56 ± 11.42	81.25 ± 13.55	0.002
Alveolar-arterial oxygen partial pressure difference(mmHg)	35.77 ± 16.00	18.1 ± 13.69	0.001	35.84 ± 15.52	28.75 ± 12.21	0.220
FVC(L)	3.34 ± 0.88	3.54 ± 0.83	0.022	3.165 ± 0.952	3.365 ± 0.849	0.139
DLCO (%)	69.65 ± 22.49	84.49 ± 13.73	0.004	68.75 ± 26.02	89.24 ± 14.70	0.010
Six-minute walking distance(miles)	501.9 ± 133.22	645 ± 117.18	0.002	486.0 ± 134.0	624.0 ± 149.7	0.021

FVC Forced vital capacity, DLCO Carbon monoxide diffusion capacity
Pulmonary function, blood gas analysis and six-minute walking distance test results (mean ± standard deviation)

ISSN: 1465-993X